KNSA Stock Summary and Trading Ideas (Kiniksa Pharmaceuticals International PLC - Class A | NASDAQ:KNSA)

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Kiniksa Pharmaceuticals International PLC - Class A trades on the NASDAQ stock market under the symbol KNSA.

As of November 13, 2026, KNSA stock price climbed to $96.33 with 441,566 million shares trading.

KNSA has a beta of -0.00, meaning it tends to be less sensitive to market movements. KNSA has a correlation of 0.00 to the broad based SPY ETF.

KNSA has a market cap of $7.57 billion. This is considered a Mid Cap stock.

Last quarter Kiniksa Pharmaceuticals International PLC - Class A reported $286 million in Revenue and $.56 earnings per share. This beat revenue expectation by $26 million and exceeded earnings estimates by $.23.

In the last 3 years, KNSA traded as high as $99.31 and as low as $15.05.

The top ETF exchange traded funds that KNSA belongs to (by Net Assets): IWM, VTI, VB, IWO, VBK.

KNSA has outperformed the market in the last year with a price return of +139.1% while the SPY ETF gained +13.4%. KNSA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +23.8% and +4.4%, respectively, while the SPY returned -2.8% and -0.2%, respectively.

KNSA support price is $92.55 and resistance is $100.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KNSA shares will trade within this expected range on the day.